- ABOUT LCB
-
Home > ABOUT LCB > History
- 10.LegoChemBio entered into an agreement to acquire 100% stake in Khanmed (Oct 1)
- 08.LCB out-licensed anti-HER2 ADC to Fosun Pharma for the Greater China market
- 11.LCB raised KRW 19 billion ($19 million) from three VCs.
- 10.LCB01-0371 (oxazolidinone antibiotics) is selected as the second "Pharm Navi" project by Ministry Of Food And Drug Safety (MFDS). (Pharm Navi project is executed by MFDS to expedite drug development for a highly competitive drug pipeline. Fast-track)
- 09.Completed Phase 1 of LCB02-0133 FXa inhibitor in the U.S.
- Commence Phase 1 of LCB01-0371 (IV) in the U.S.
- Commence preclinical studies of LCB01-0699 (next-generation oxazolidinone antibiotics) in Medicilon in China.
- Commence in-vivo studies of a novel oncology project in collaboration with Sanofi.
- 08.LCB is designated as K-Brain Power Company by Ministry of Trade, Industry and Energy.
- 04.LCB is certified as a Venture Invested Company by Korea Venture Capital Association.
- 01.Additional licensing-out agreement for a mono therapy with AstraZeneca for LCB10-0200 (gram-negative antibiotics).
- 08.Commence preclinical studies of LCB10-0200 (gram-negative cephalosporin antibiotics) in the U.K.
- Commence Phase 1(b) of FXa inhibitor in the U.S.
- 07.LCB's Antibody-Drug Conjugate (ADC) was selected as an investment-related project by the Small and Medium Business Administration (SMBA).
- LCB raised KRW 1 billion ($1 million) through convertible bonds.
- 05.LegoChem Biosciences made Initial Public Offering (IPO) on KOSDAQ.
- LegoChem Biosciences moved its headquarter to 8-26 Munpyeongseo-ro Daedeok-gu Daejeon, Korea
- 03.filed a registration statement with the Korea Exchange.
- 02.LCB10-0200 (gram-negative antibiotics) is granted a cross-government drug development fund that provides funding on the all stages of new drug discovery and development.
- 12.Licensing and collaboration agreement with AstraZeneca for LCB10-0200 (gram-negative antibiotics)
- Licensing-out agreement with Green Cross for Antibody-Drug Conjugate (ADC)
- LegoChem Biosciences received KOSDAQ approval for IPO
- 11.Global collaboration and licensing-out agreement for LCB01-0699 (next-generation oxazolidinone antibiotics) with Medicilon for China market.
- LegoChem Biosciences raised fourth venture capital fund.
- LegoChem Biosciences successfully completed a technology evaluation for IPO by KOSDAQ
- 09.Licensing-out and collaboration agreement with NeoPharm for Antibody-Drug Conjugates (ADCs).
- Agreement with NeoPharm to provide drug substance for PAR-2 inhibitors
- 07.Collaboration research agreement with Sanofi for a novel oncology project.
- 06.LegoChem Biosciences, Inc. is designated as INNO-BIZ. (INNO-BIZ certification is granted by government to highly innovative SMEs with competitive technology expertise.
- 05.ADC(Antibody-Drug-Conjugates) patent applied to the U.S.
- Technology Examination (in preparation of KOSDAQ)
- 03.Nominated as “Emerging Company of the Year 2012” (BioSpectrum Asia, Singapore)
- 02.Oxazolidinones Antibiotics: Entering Phase 1 in Korea
- Oxazolidinones Antibiotics: Granted Korea Drug Development Fund.
- Anti-coagulants(FXa: GreenCross): Entering Phase 1 in U.S.
- 01.Oxazolidinoes Antibiotics: L/O at Phase 1 to DreamPharma (Local, Southeast Asia)
- Gram(-) Antibiotics: MTA with a global pharma
- 12.Korea FDA approval of IND for Antibiotics at Phase I
- 3rd round of fund raising from Korean venture capitals (3.5 billion won)
- 11.US FDA approval of IND for Anti-coagulants(FXa: GreenCross) at Phase I
- 09.U.S. Chicago, 2011 “ICAAC” Conference, presented as an invited speaker (CEO, Yong-Zu Kim)
- U.S. Chicago, 2011 “ICAAC” Conference, posters presented (Antibiotics)
- 07.Global New Drug to Drug-candidate Discovery Project.
- (Title: FXIa inhibitor) / (organized by Korean Ministry of Education, Science, and Technology)
- 05.Agentship contract for the transfer of technology with NeoPharm (China)
- 02.Antibiotics(FXa inhibitor) pre-clinical is completed (by GreenCross)
- 12.Agentship contract for the transfer of technology with East R&D and across the U.S.
- Oxazolidinones Antibiotics pre-clinical is completed
- 10.Joint research contract with Interprotein (Japan) (Title: VEGF inhibitors)
- 09.U.S. Boston, 2010 “ICAAC” Conference, posters presented (Antibiotics)
- 07.Contract with underwriter for IPO (Korea Investment & Securities Co. Ltd,.)
- 12.U.S. San Francisco, 2009 “ICAAC” Conference, posters presented (Antibiotics)
- Awarded Distinction by DaeDeok Innopolis Foundation (Anti-coagulant: FXa inhibitor)
- 06.Government Research Grant (gram(-) Antibiotics for IND filling)
- L/O a pre-clinical candidate (Anti-coagulants: FXa inhibitor) to GreenCross
- 05.Received ‘The Scientist of This Month Award’ (Ph.D Song, Ho Yong)
- 2nd round of fund raising from Korean venture capitals (4 billion won)
- 03.Paper on anticancer(HSP90) published in JCI (Joint research with U. Mass)
- 01.Joint research contract with The Catholic Univ. School of Medicine (ophthalmic medicine: Wondonin)
- 08.Agentship contract with SPI (Sumitomo Subsidiary) for Japan Market
- 07.Satellite Lab established at Young-nam Univ.
- 05.Government Research Grant for Innovative New Drug under the MOHW (Title: Oxazolidinones Antibiotics) / * MOHW: Ministry of Health and Welfare
- 02.Joint research contract with BRN Science
- (Anticancer HSP90 inhibitors) / (BRN : its former name: Newgex)
- 09.U.S. Chicago, 2007 “ICAAC” Conference, posters presented (Antibiotics)
- 08.Anti-coagulant Daejok Innopolis Technology Business Project
- (Title: FXa inhibitor)
- 04.Research contract with U. Mass (mitochondriotropic HSP90 inhibitor)
- 03.1st round of fund raising from Korea venture capitals (4.5 billion won)
- 12.Joint research contract with Yonsei Univ. Molecular design lab (Anti-coagulants: FXa, FVIIa inhibitor)
- Patents relating to antibiotic and anti-coagulant (one each)
- 11.Joint research contract with KIST (Anticancer DDR-2)
- 05.Established at DBVT (Daejon BioVenture Town, Daejon, Korea)
